126 related articles for article (PubMed ID: 26492053)
1. High Incidence of Paralytic Ileus After Bortezomib Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients: Report of 2 Cases.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Cid J; Lozano M; Campistol JM; Oppenheimer F
Transplantation; 2015 Nov; 99(11):e170-1. PubMed ID: 26492053
[No Abstract] [Full Text] [Related]
2. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
3. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor.
Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH
Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661
[TBL] [Abstract][Full Text] [Related]
4. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
6. Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.
Gheith O; Al-Otaibi T; Nampoory N; Halim M; Nair P; Saied T; Al-Waheeb S; Muzeirei I; Ibraheim M
Exp Clin Transplant; 2012 Aug; 10(4):406-9. PubMed ID: 22746156
[TBL] [Abstract][Full Text] [Related]
7. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
8. [Paralytic ileus].
Kinoshita Y; Saitoh T; Ishihara S
Nihon Rinsho; 2012 Aug; 70 Suppl 6():557-60. PubMed ID: 23156571
[No Abstract] [Full Text] [Related]
9. The role of splenectomy in the setting of refractory humoral rejection after kidney transplantation.
Tzvetanov I; Spaggiari M; Jeon H; Roca RG; Bhati C; Oberholzer J; Benedetti E
Transplant Proc; 2012 Jun; 44(5):1254-8. PubMed ID: 22663995
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
Claes DJ; Yin H; Goebel J
Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
12. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
Keating M; Dasanu CA
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27899388
[TBL] [Abstract][Full Text] [Related]
13. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options.
Kim M; Martin ST; Townsend KR; Gabardi S
Pharmacotherapy; 2014 Jul; 34(7):733-44. PubMed ID: 24753207
[TBL] [Abstract][Full Text] [Related]
14. Chronic antibody-mediated rejection: review of literature.
Hassan R; Gheith O
Iran J Kidney Dis; 2014 Mar; 8(2):93-103. PubMed ID: 24685730
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases.
Roberti I; Vyas S
Pediatr Transplant; 2015 Dec; 19(8):E189-92. PubMed ID: 26455511
[TBL] [Abstract][Full Text] [Related]
16. Paralytic ileus following "subcutaneous bortezomib" therapy: focus on the clinical emergency-report of two cases.
Mele G; Coppi MR; Melpignano A; Quarta G
Clin Exp Med; 2016 Feb; 16(1):99-101. PubMed ID: 25600700
[TBL] [Abstract][Full Text] [Related]
17. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
18. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG
Clin Transpl; 2009; ():465-9. PubMed ID: 20524316
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
[TBL] [Abstract][Full Text] [Related]
20. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
